Corporate venture funds fill drop off in biotech investment

11/15/2011 | Bloomberg Businessweek

Corporate venture funds are increasingly filling biotech firms' funding needs, according to analysts. Corporate venture funds were tied to 25% of early-stage U.S. biotech financing deals during the first half of 2011, compared with 15% in all of 2010, according to PricewaterhouseCoopers and the National Venture Capital Association. Amgen Ventures said it has funded 26 companies since it started in 2004.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
In house Compliance Officer
Confidential
Pompano Beach, FL